ZSCAN20 and laryngotracheoesophageal cleft: We can collect more clinical data to further explore the development of HCC, analyzing the expression of ZSCAN20 in HCC tissues, LC tissues and CH tissues and whether ZSCAN20 can be used as a biomarker to distinguish HCC tissues, LC tissues and CH tissues.